Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains
#Supernus Pharmaceuticals #Cantor Fitzgerald #ONAPGO #Overweight rating #Supply gains #Parkinson's treatment #Earnings report
📌 Key Takeaways
- Cantor Fitzgerald maintains Overweight rating with $63 price target on Supernus
- Supernus reported 2025 revenues of $719 million, beating consensus estimates
- ONAPGO supply gains and 2026 sales guidance of $45-70 million
- Company expected to turn profitable in 2026 with $2.59 EPS forecast
- Stock surged 62% over past year to $53.30
📖 Full Retelling
Cantor reiterated an Overweight rating and $63.00 price target on Supernus Pharmaceuticals (NASDAQ:SUPN) stock on February 25, 2026, following the company's positive earnings report and strengthened supply position for its Parkinson's disease treatment ONAPGO. Supernus reported impressive 2025 revenues of $719 million, surpassing analyst expectations of $703 million, driven by stronger-than-anticipated sales of ZURZUVAE and ONAPGO. The company's stock has surged 62% over the past year to $53.30, reflecting growing investor confidence in its product portfolio and future prospects. According to analyst forecasts, Supernus is positioned to turn profitable this year with projected earnings of $2.59 per share, marking a significant reversal from the previous year's losses. The pharmaceutical firm secured additional supply of ONAPGO from its current supplier and is actively working to secure a second supplier who could begin providing the medication in 2027. Supernus guided for ONAPGO sales ranging from $45 million to $70 million in 2026, benefiting from an impressive gross profit margin of 90%. While Cantor Fitzgerald highlighted the supply update for ONAPGO as the key focus of the earnings results, other financial firms have also weighed in on the company's performance, with Stifel adjusting its price target upward to $55.00 while maintaining a Hold rating, citing the company's successful navigation of a patent cliff and development of a robust product portfolio.
🏷️ Themes
Pharmaceutical supply, Financial analyst ratings, Market performance
📚 Related People & Topics
Cantor Fitzgerald
American financial services company
Cantor Fitzgerald, L.P. is an American financial services firm that was founded in 1945. Cantor Fitzgerald's 1,600 employees work in more than 30 locations, including financial centers in the Americas, Europe, Asia-Pacific, and the Middle East. Together with its affiliates, Cantor Fitzgerald operate...
Entity Intersection Graph
Connections for Cantor Fitzgerald:
🌐
Conflict of interest
1 shared
🏢
USA Rare Earth
1 shared
👤
Howard Lutnick
1 shared
🏢
Mercado Libre
1 shared
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Nvidia, Salesforce earnings loom large - what’s moving markets Gold prices rebound on tariff jitters; silver, platinum and copper rally Nvidia set to report strong results and guidance, analysts say U.S. stock futures drift higher; Nvidia earnings to drive direction (South Africa Philippines Nigeria) Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains By Investing.com Analyst Ratings Published 02/25/2026, 07:50 AM Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains 0 SUPN 5.15% Investing.com - Cantor Fitzgerald reiterated an Overweight rating and $63.00 price target on Supernus Pharmaceuticals (NASDAQ:SUPN) stock following the company’s fourth-quarter and full-year 2025 earnings report. Supernus reported 2025 revenues of $719 million, beating the consensus estimate of $703 million. The revenue beat was driven primarily by stronger-than-expected sales of ZURZUVAE and ONAPGO. The stock has surged 62% over the past year to $53.30, reflecting investor confidence in the company’s product portfolio. According to InvestingPro data, analysts predict the company will turn profitable this year with forecasted earnings of $2.59 per share, a significant turnaround from last year’s loss. The company secured additional supply of ONAPGO, its Parkinson’s disease treatment, from its current supplier. Supernus guided for ONAPGO sales of $45 million to $70 million in 2026. With an impressive gross profit margin of 90% and analysts maintaining a Strong Buy consensus, InvestingPro analysis suggests the stock remains slightly undervalued at current levels. Supernus is working to secure a second supplier for ONAPGO who could begin providing supply in 2027. The company did not pre-announce any revenues or metrics earlier this year. Cantor Fitzgerald noted the supply update for ONAPGO was the biggest focus of the earnings call and results. In other recent news, Supernus Pharmaceuticals has amende...
Read full article at source